[Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?].
Identifieur interne : 000102 ( Main/Corpus ); précédent : 000101; suivant : 000103[Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?].
Auteurs : Angelika BischoffSource :
- MMW Fortschritte der Medizin [ 1438-3276 ] ; 2015.
English descriptors
- KwdEn :
- Ambulatory Care, Antiviral Agents (therapeutic use), Cause of Death, Evidence-Based Medicine, Germany, Hospitalization, Humans, Influenza, Human (classification), Influenza, Human (diagnosis), Influenza, Human (drug therapy), Influenza, Human (mortality), Neuraminidase (antagonists & inhibitors), Oseltamivir (therapeutic use), Survival Analysis, Zanamivir (therapeutic use).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , therapeutic use : Antiviral Agents, Oseltamivir, Zanamivir.
- geographic : Germany.
- classification : Influenza, Human.
- diagnosis : Influenza, Human.
- drug therapy : Influenza, Human.
- mortality : Influenza, Human.
- Ambulatory Care, Cause of Death, Evidence-Based Medicine, Hospitalization, Humans, Survival Analysis.
DOI: 10.1007/s15006-015-3565-5
PubMed: 26759863
Links to Exploration step
pubmed:26759863Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?].</title>
<author><name sortKey="Bischoff, Angelika" sort="Bischoff, Angelika" uniqKey="Bischoff A" first="Angelika" last="Bischoff">Angelika Bischoff</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26759863</idno>
<idno type="pmid">26759863</idno>
<idno type="doi">10.1007/s15006-015-3565-5</idno>
<idno type="wicri:Area/Main/Corpus">000102</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000102</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?].</title>
<author><name sortKey="Bischoff, Angelika" sort="Bischoff, Angelika" uniqKey="Bischoff A" first="Angelika" last="Bischoff">Angelika Bischoff</name>
</author>
</analytic>
<series><title level="j">MMW Fortschritte der Medizin</title>
<idno type="ISSN">1438-3276</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ambulatory Care</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Cause of Death</term>
<term>Evidence-Based Medicine</term>
<term>Germany</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Influenza, Human (classification)</term>
<term>Influenza, Human (diagnosis)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (mortality)</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Oseltamivir (therapeutic use)</term>
<term>Survival Analysis</term>
<term>Zanamivir (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Oseltamivir</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Ambulatory Care</term>
<term>Cause of Death</term>
<term>Evidence-Based Medicine</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Survival Analysis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26759863</PMID>
<DateCompleted><Year>2016</Year>
<Month>02</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>09</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1438-3276</ISSN>
<JournalIssue CitedMedium="Print"><Volume>157</Volume>
<Issue>17</Issue>
<PubDate><Year>2015</Year>
<Month>Oct</Month>
<Day>08</Day>
</PubDate>
</JournalIssue>
<Title>MMW Fortschritte der Medizin</Title>
<ISOAbbreviation>MMW Fortschr Med</ISOAbbreviation>
</Journal>
<ArticleTitle>[Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?].</ArticleTitle>
<Pagination><MedlinePgn>24</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bischoff</LastName>
<ForeName>Angelika</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>ger</Language>
<PublicationTypeList><PublicationType UI="D016433">News</PublicationType>
</PublicationTypeList>
<VernacularTitle>Evidenz auf dem Prüfstand. Neuraminidasehemmer bei schwerer Grippe: ja oder nein?</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>MMW Fortschr Med</MedlineTA>
<NlmUniqueID>100893959</NlmUniqueID>
<ISSNLinking>1438-3276</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>L6O3XI777I</RegistryNumber>
<NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>1</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>1</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26759863</ArticleId>
<ArticleId IdType="doi">10.1007/s15006-015-3565-5</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=ExplorPubmed/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000102 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000102 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= *** parameter Area/wikiCode missing *** |area= ExplorPubmed |flux= Main |étape= Corpus |type= RBID |clé= pubmed:26759863 |texte= [Evidence under scrutiny. Neuraminidase inhibitors in severe influenza: yes or no?]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:26759863" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a ExplorPubmed
![]() | This area was generated with Dilib version V0.6.35. | ![]() |